A Phase I study to evaluate safety and tolerability of DTaP-IPV + Hibvaccine in healthy adult volunteers in India. To assess safety and tolerability of a diphtheria and tetanus toxoid, acellular pertussis, inactivated poliovirus and conjugate adsorbed vaccine (DTaP-IPV + Hib), manufactured by Serum Institute of India Pvt. Ltd. (SIIPL)'s, the current first-in-human Phase 1 study was conducted and recovered completely. No deaths, unsolicited adverse events, or serious adverse events were reported. SIIPL DTaP-IPV + Hibvaccine was well tolerated and safe in study subjects. Further clinical development will be conducted to assess safety and immunogenicity in young children, the target population. CTRI/2017/07/009034.
The Immunogenicity and Safety of a Combined DTaP-IPV//HibVaccine Compared with Individual DTaP-IPV and Hib (PRP~T) Vaccines: a Randomized Clinical Trial in South Korean Infants. Recommended infant vaccination in Korea includes DTaP-IPV and Hib vaccines administered as separate injections. In this randomized, open, controlled study we assessed the non-inferiority of immunogenicity of DTaP-IPV . The immunological non-inferiority and similar safety profile of DTaP-IPV//Hibvaccine to separate DTaP-IPV and Hib vaccines, with the advantage of fewer injections and injection site reactions, supports the licensure and incorporation of DTaP-IPV//Hib into the Korean national vaccination schedule (Clinical trial registry, NCT01214889).
vaccines to reduce the number of injections and simplify the immunization schedule. This study aimed to investigate the current status of the pentavalent diphtheria-tetanus-acellular pertussis inactivated poliomyelitis and Haemophilus influenzae type B conjugate (DTaP-IPV/Hib) vaccination in Southern China as well as explore the factors in the general population associated with uptake and the differences questionnaire. Multivariate logistic regression was used to determine the factors associated with the status of DTap-IPV/Hibvaccinations. Of the 4818 valid responses, 95.3% of children were aged 3-4 years, and 2856 (59.3%) held rural hukou. Coverage rates of the DTaP-IPV/Hibvaccine, from 1 to 4 doses, were 24.4%, 20.7%, 18.5%, and 16.0%, respectively. Caregivers who are concerned about vaccine efficacy
acellular pertussis preparation.Children of one to ten years who have completed a primary course (which includes three doses of diphtheria, tetanus and polio), but have not received three doses of a pertussis-containing vaccine should be offered an extra dose of combined DTaP/IPV (or DTaP/IPV/Hib) vaccine to provide some priming against pertussis. The dTaP/IPV vaccine, which
Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017. The DTaP-IPV/Hib combination vaccine can replace the acellular tetanus vaccine, polio vaccine, and the Haemophilus influenzae type B vaccine. Data on the safety of DTaP-IPV/Hibvaccines are required. We aimed to evaluate the safety of the vaccination program. Using the National Adverse Events Following Immunization (AEFI) surveillance system (CNAEFIS) in Guangzhou, China, a retrospective study was performed from May 11, 2011, to December 31, 2017. There were 376 cases of adverse events after vaccination with the DTaPIPV/Hibvaccine. The primary analysis indicators were the number of vaccines used, the number of AEFI reports received, and the reporting rate (per
Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. Globally, the use of single DTaP-IPV/Hibvaccines that combine DTaP-IPV and Hib is widespread, but in Japan vaccination is usually concomitant at separate sites. The immunogenicity and safety of a primary vaccination series and booster of a combined pentavalent DTaP-IPV/Hibvaccine were evaluated and compared to separate administration of DTaP-IPV and Hib in Japanese infants. Healthy Japanese infants were administered DTaP-IPV/Hib (Group A: N = 207) or DTaP-IPV + Hib (Group B: N = 207) by the subcutaneous (SC) or DTaP-IPV/Hib by the intramuscular (IM) route (Group C: N = 10). All subjects received a 3-dose primary vaccination series and a booster. Non
Hib vaccination was introduced into the UK routine childhood immunisation schedule in 1992. In 1996, the single Hib vaccine was replaced by a diphtheria, tetanus, pertussis and Haemophilus influenzae type b (DTP/Hib) combination. The original DTP/Hib combination was replaced by the current diphtheria, tetanus, acellular pertussis/inactivated polio/Haemophilus influenzae type b (DTaP/IPV/Hib) vaccine vaccines are composed of capsular polysaccharide from cultured Haemophilus influenzae type b bacteria, conjugated to protein to strengthen immunogenicity.The Hib vaccine is available as:DTaP/IPV/Hib vaccine.Hib/meningitis C (Hib/MenC) combined vaccine.Although the current DTaP/IPV/Hibvaccine contains an acellular pertussis component, the preparation does induce an effective immunological response to Hib
/IPV/Hib) vaccine to provide some priming against pertussis.They should then receive the first reinforcing dose as scheduled, also as DTaP/IPV (or DTaP/IPV/Hib), preferably allowing a minimum interval of one year.Similarly, children who present first for the preschool booster without any pertussis, should also receive DTaP/IPV (or DTaP/IPV/Hib) as priming and reinforcing doses, preferably allowing the remaining doses. DTaP/IPV/Hib should be used to complete a primary course that has been started with a whole-cell or another acellular pertussis preparation.Children of 1 to 10 years, who have completed a primary course (which includes three doses of diphtheria, tetanus and polio) but have not received three doses of a pertussis-containing vaccine, should be offered a dose of combined DTaP/IPV (or DTaP
in comparison with DTwP/Hib combinations (Trotter et al., 2003). The Hib-containing vaccine (Pediacel) chosen for primary immunisation in the UK programme has been shown not to have this problem (Miller et al., 2003). The Hib vaccine is given as part of a combined product: ●● diphtheria/tetanus/acellular pertussis/inactivated polio vaccine/ H. influenzae type b (DTaP/IPV/Hib) vaccine, or ●● Hib/MenC (see below). For children over one year of age and under ten years of age who have either not been immunised or not completed a primary course of diphtheria, tetanus, pertussis or polio, DTaP/IPV/Hibvaccination should be used. Children over one year and under ten years of age who have completed a primary course of diphtheria, tetanus, pertussis or polio
-Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine as the most recent vaccine was associated with less childhood asthma and fewer acute hospital contacts for childhood asthma among boys and girls. This study is a nationwide register-based cohort study of 338 761 Danish children born between 1999 and 2006. We compared (i) the incidence of first-registered childhood asthma based on hospital contacts
receipt of DTaP-IPV-Hibvaccine 1st dose. This study assessed age-appropriate childhood vaccination coverage in a national cohort of children. While the overall vaccination coverage stands in line with the WHO goals, vaccination timeliness and equity are inadequate and targeted public health intervention programs aimed at vaccination timeliness are necessary.
on the DTaP-IPV/Hib Pentavalent Vaccine Basic Immunization Strategy Optimization Study Cohort ("Pentavalent Vaccine Cohort") and the Epidemiological Investigation of Carrying Status of Pathogens Causing Acute Respiratory Infections (ARIs) in Infants and Young Children Cohort ("Pathogen Surveillance Cohort"). DTaP-IPV/Hibvaccine basic immunization strategy optimization study is a single-center, randomized
at the same visit) with live and inactivated vaccines may increase child mortality compared with the live vaccine alone. We examined the hypothesis that simultaneous administration of MMR and the inactivated DTaP-IPV-Hibvaccine compared with MMR alone is associated with higher incidence of infectious disease admissions. Nationwide, retrospective, register based cohort study of 520,859 children born
obesity (10–11-year-olds), and in the rates of young people being admitted to hospital due to substance misuse (15–24-year-olds), and for self-harm (10–24-year-olds).Three indicators – the proportion of 1–2-year-olds receiving the five-in-one vaccination (DTaP/IPV/Hibvaccination); hospital admissions for asthma (for under 19-year-olds); and family homelessness (a broader determinant of health outcomes admissions for tooth decay (in 0–4-year-olds), and the proportion of children (0–18 years) in care increased for England overall, and in the least deprived areas, but respectively improved and remained static in the most deprived areas.Counterintuitively, this has led to the disappearance of the health inequality gap for DTaP/IPV/Hibvaccinations, and a narrowing of the health inequality gap for the other
vaccination and were measured in group 2 at one and seven months post-MCC vaccination. Antibodies elicited by diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine and Haemophilus influenzae b conjugate (DTaP-IPV-Hib) vaccine coadministered at the 18-month vaccination were measured one month later. Safety data were collected. At 19 months